Parkman Healthcare Partners LLC Buys New Shares in Artivion, Inc. $AORT

Key Points

• Parkman Healthcare Partners purchased 138,940 Artivion shares worth approximately $3.1 million, representing a 0.28% stake. Institutional investors and hedge funds collectively own 86.37% of the company.
• Analysts maintain a generally positive outlook, with seven Buy ratings and one Sell rating, producing a consensus “Moderate Buy” rating and an average price target of $44.83.
• Artivion reported quarterly revenue of $125.76 million, above expectations, and earnings of $0.13 per share. The stock opened at $27.07, while insiders—including the CEO—have sold approximately 114,978 shares valued at $3.0 million over the past 90 days.

Parkman Healthcare Partners LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 138,940 shares of the company's stock, valued at approximately $3,122,000. Parkman Healthcare Partners LLC owned 0.28% of Artivion at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the 3rd quarter valued at about $27,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after acquiring an additional 399 shares during the period. Larson Financial Group LLC boosted its position in shares of Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after acquiring an additional 563 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares during the period. Finally, Kemnay Advisory Services Inc. purchased a new stake in Artivion in the fourth quarter valued at approximately $79,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on AORT shares. Citizens Jmp dropped their price target on shares of Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research report on Friday, May 8th. Citigroup reiterated a "market outperform" rating on shares of Artivion in a report on Tuesday, July 21st. Needham & Company LLC reissued a "buy" rating and set a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Canaccord Genuity Group upped their price objective on Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, August 18th. Finally, Wall Street Zen lowered Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Artivion currently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

Artivion Stock Down 3.6%

AORT opened at $27.07 on Tuesday. The firm has a 50 day moving average price of $25.20 and a 200 day moving average price of $29.96. The company has a market cap of $1.32 billion, a PE ratio of -386.66 and a beta of 1.24. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The firm had revenue of $125.76 million for the quarter, compared to analysts' expectations of $119.99 million. Sell-side analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Insider Activity

In related news, CEO James P. Mackin sold 70,000 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company's stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the firm's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the transaction, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. This trade represents a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 114,978 shares of company stock valued at $2,965,155. Company insiders own 6.30% of the company's stock.

Artivion Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source